Abstract
Background
Tuberculosis (TB) is considered one of the most infectious diseases in the world. In this study, we intended to examine the epidemiology of tuberculosis by MIRU-VNTR to define the changes that occur in the transmission of tuberculosis in the region during the COVID-19 era. A total of 120 Mycobacterium tuberculosis isolates were collected from sputum samples of patients referred to East Azerbaijan Center TB from December 2020 to August 2021. Demographic information such as age, sex, place of birth, previous TB history, and relevant medical data was collected. The proportion method was performed for drug susceptibility testing, and the PCR-based MIRU-VNTR method was applied to identify molecular epidemiology relationships.
Results
The isolates were collected from 78 male (65%) and 39 female (32.5%) Iranian patients and 3 (2.5%) Azerbaijani patients. Ninety-three distinct patterns were identified including 15 clustered patterns and 36 unique patterns. The largest cluster was composed of seven isolates. Furthermore, one cluster with 5 members, four clusters with 3 members, and nine clusters with 2 members. In MIRU-VNTR typing, 75 clusters belonged to the Tabriz region and just 3 to the Republic of Azerbaijan. All isolates were sensitive to rifampin, isoniazid, and ethambutol.
Conclusions
Results of the current study showed COVID-19 pandemic had a direct effect on the transmission and diagnosis of tuberculosis. Less diagnosis and less clustering can indicate public controls and hygiene, and the use of masks had a direct effect on the transmission and diagnosis of tuberculosis. However, misidentification and less focus on other respiratory infections are expected during the pandemic. Studies on the co-infection of COVID-19 and tuberculosis and the role of mask and sanitization against TB are strongly recommended.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tabriz University of Medical Sciences, Student Research Committee, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)
2 Tabriz University of Medical Sciences, Drug Applied Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)
3 Tabriz University of Medical Sciences, Immunology Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)
4 Tabriz University of Medical Sciences, Drug Applied Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913); Tabriz University of Medical Sciences, Biotechnology Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)
5 Tabriz University of Medical Sciences, Research Center for Pharmaceutical Nanotechnology, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)
6 Tabriz University of Medical Sciences, Biotechnology Research Center, Tabriz, Iran (GRID:grid.412888.f) (ISNI:0000 0001 2174 8913)





